ARS Pharmaceuticals Inc. (NASDAQ:SPRY)

There are currently no videos for this stock.
To request coverage of this stock, please click the green request video box on the right.
Bands Volume 200 SMA 50 SMA 20 SMA Videos Alerts Articles Events
SPRY Weekly Chart

Old Forum Content for SPRY

Make a Forum Post
Become a member to view recent forum posts. Already a member? Sign in here.
Loading...
  • Onthemark: $SPRY Keep an eye out for this one as it pulls back on very low volume right to the 21dema and holding just above the prior low on Monday of 13.77. has been knocking on the resistance level of 15.
  • Onthemark: $SPRY hit 15 yesterday - resistance; however, not falling back hard as it has in the past when reaching this point. Seems as though the sellers have dried up, and yesterday's close was the highest since last November. Forming a flag that may be ready to move again once the 8d catches up.
  • Onthemark: Added to $SPRY 12.27, $CAVA 75.48 and $SE 105.93
  • Onthemark: @Onthemark $SPRY $CAVA $SE They are moving pretty well: $SPRY 13.39, $CAVA 81.68 and $SE 110.16
  • Onthemark: $SPRY at HOD above all MA's. Heading up to 14 in the very short term. Shouldn't have any problem with tariffs. Those with severe allergies still need epinephrine.
  • PhilHarmonic: $SPRY Up through the 200 dma on large volume. Earnings beat and high short int. NP
  • Onthemark: @PhilHarmonic $SPRY Holding a huge amount Long, up 27%. Make my day!
  • Onthemark: $SPRY a very nice reverse H&S pattern with resistance at 15. Look for this one to either flag or move up on day 2. Long from way back. Made a lot on this one last year, looking for repeat this year. Huge volume today up 21% after pulling back from today's high.
  • Onthemark: $SPRY broke above 200d, formed a nice cup, not sure when or if a handle will begin.
  • Onthemark: $SPRY received FDA approval for lower dose spray for small children. Day 3 up move.
  • Onthemark: A #U-turn possibility is $SPRY. They have a few presentations coming up with their approved neffy nasal spray, and have a conf call set for 3/20 pre-market to present their 4th qrt ER.
  • Onthemark: Strong ones today holding Long: $SPRY, $LABU, and $NAIL
  • Onthemark: Keep $SPRY on a watch list as it is now under accumulation above the 200d. A bottom fish that may be headed to the surface
  • dusty: @Onthemark $SPRY Doc friend mentioned they have a nasal antidote for Opioid that could be Huge with more stuff in pipeline...worth watching!
  • Onthemark: $SPRY bouncing off the 21dema after a 3 day pullback. Low volume but looks ready to start another upswing once it passes the 8dema, and will then add.
  • Onthemark: $SPRY another new high 16.89
  • Onthemark: @Onthemark $SPRY Pulled back after making the NH. Now waiting for the stock to settle under 16 and add on the next bounce
  • Onthemark: $SPRY new high today.
  • Onthemark: Took some profits in $SPRY at 16.61
  • Onthemark: $SPRY up nice on a down day. They entered into agreement with European Co. for more vials in the sale of the product.
  • Onthemark: Reduced exposure and now holding just a few: $SPRY, $VKTX, $GTLS, $SMCI and $CPA.
  • joelsg1: @Onthemark $SPRY $VKTX $GTLS $SMCI $CPA $SMCI traded (publicly) over 100M shares today.
  • Onthemark: $SPRY reverse head and shoulders, now selling their product.
  • Onthemark: My really big money maker this year has been $SPRY. Back on 9/11, I posted that it was ready to move and it was at 12. Been in this since May 2023, but didn't start making money until Sept 2023. Now it is back at resistance and took some more profits. Watching for either a breakout to ride higher, or pullback to sell into, then buy at the next bounce. This stock is still just in the early stages of a big future in the world epinephrine nose spray market, which it is the only company to produce this product. I expect a pullback since they are not yet making any money, so this is more a suggestion to add to your watch list.
  • Onthemark: Holding just a few in the trading acct: $SPRY (large position/low risk basis), $VKTX, $SG and $HUMA.
  • Onthemark: $SPRY Pullback to the 50d now completed and now holding it. FDA and EU approval obtained and getting ready to make sales in the next few weeks. Huge upside to the needle-free epinephrine market. The overhead supply is institutions that got in once approvals were announced. Large insider positions. Been a great money maker for me, and the story is just beginning.
  • Onthemark: Holding through next week: $AEM, $AMZN, $GE, $OLLI, $SPRY and $VKTX
  • Onthemark: $SPRY making a Phase 3 flag above the 8dema. Had 3 huge volume buys in Aug.
  • Onthemark: $SPRY up about 75 percent in 10 days, and plenty of upside to go.
  • Onthemark: $SPRY Took 1/2 profits at $13.25. Up 45 percent in last 8 days.
  • Onthemark: $SPRY to jump 11percent on the open. Took some profits at 11.98, didn't want to lose the jump. It's coming back in so will reload at lower prices.
  • Onthemark: $SPRY: Took some profits now at 12.54.
  • woodman: @MongosPawn $AQST - interesting move in AQST given $SPRY's action since getting its epi spray approved on Friday.
  • Onthemark: $SPRY closing at HOD over $13. All time high was $63.41 back on 3/18/21.
  • Onthemark: Update on $SPRY: ARS Pharmaceuticals won Food and Drug Administration approval of its neffy nasal spray for the emergency treatment of allergic reactions, including life-threatening anaphylaxis. The FDA on Friday said the approval, which covers neffy for adults and children who weigh at least 30 kilograms, makes neffy the first epinephrine product for the treatment of anaphylaxis that isn't administered by injection. ARS earlier this week said commercial-readiness efforts were well underway to support the launch of neffy upon FDA approval, and the company also expected to win European regulatory approval of the product during the third quarter.
  • joelsg1: @Onthemark $SPRY Holding above 10% pop on news. Roadmap for $HUMA?
  • joelsg1: @woodman $HUMA Check out $SPRY moving on its FDA news.
  • woodman: @joelsg1 $HUMA $SPRY - I saw earlier. Perhaps a probelm for $AQST? In any event, we better get a much better pop than 10% if $HUMA's "ATEV" (formerly "HAV") is approved. Way too much risk for measly 10-12%. By the way, why would the FDA tell HUMA to change the name of the product only to issue a CRL? Maybe it's meaningless, I don't know. Everyone is reading evry shard of a tea leaf here in the home stretch.
  • joelsg1: @woodman $HUMA $SPRY $AQST Oh yes, I have a min. measured move to at least $9.50 and hope that's low.
  • Onthemark: $SPRY My little biotech bounced just where I thought it would.
  • Onthemark: $SPRY giving a chance to get in on this pull back day. Could retrace down to 11, but too many buyers out there. My largest position.
  • Onthemark: $SPRY made a New High today and has been riding the top of the bollinger band this week. Took some profits at 11.33, bought back at 10.77 and ready to take some more off the table. This one will really move once the EU approval is received in the 3rd qrt, perhaps by Sept. and FDA approval by Oct. 2nd.
  • Onthemark: $SPRY up a $1 in the PM
  • Onthemark: Liking $ULTA, $LABU and $SPRY
  • Onthemark: $SPRY just flying, woohoo, $10.30
  • Onthemark: My best today are $QURE, $VKTX and $SPRY. Also been adding to $LABU .
  • Onthemark: @Onthemark $RIVN $INSM $EVR $NVDA $META Thanks for sharing. Would add $LLY, $SPRY, and $LABU
  • SophAgogo: @Onthemark $RIVN $INSM $EVR $NVDA $META $LLY $SPRY $LABU Good call on LLY ... I had hopped out of $NVO ... trying to figure out whether $LABU will break out, it's been a painful position in the past
  • Onthemark: To Bert953 and geotheo: did you guys keep any $SPRY from earlier mentions in the Forum? At $10.62 right now.
  • Onthemark: Took some profits in $SPRY from $8 last week to $9.50 today. Resting at top of BB, will go much higher after approvals are announced.
  • Onthemark: $SPRY more buying just now in the stock, hitting $9. On a roll since the EU regulator approval
  • Onthemark: $SPRY pretty nice bounce on Friday on 4.7 million shares. EU regulatory recommends approval. FDA now working on the labeling for its anticipated approval.
  • Onthemark: $SPRY: Today's news that should move the stock: 1) ARS Pharmaceuticals' Adrenaline Nasal Spray Receives EMA Committee's Positive Opinion. 2) EU regulator recommends approval for ARS pharma's nasal spray alternative to EpiPen. 3) ARS Pharmaceuticals Says CHMP Of European Medicines Agency Adopted Positive Opinion On Application For Marketing Authorization For EURneffy (Adrenaline Nasal Spray)
  • Onthemark: @Onthemark $SPRY Back to no change after first minute pop. Shorts still in control. Been a long term holder and been taking profits and adding when the price falls below $8. Quoting Petty, "The waiting is the hardest part".
  • Onthemark: $SPRY heading up, now at 8.35, 3.75 percent
  • Onthemark: @Onthemark $SPRY At HOD 8.66, double bottom bounce heading to the 50d. Little resistance now at 8.60, then perhaps a push to the 50d at 8.75. Looking for resistance at the 50d, then next leg up once through the 50d.
  • Onthemark: $SPRY may have found a bottom
  • geotheo: $SPRY keep watching... $SPRY had breakout/fakeout from a tight squeeze (Mentioned in strat sess on Monday) and has since pulled back.
  • Bert953: @geotheo $SPRY lovely tight squeeze. Chalkin money flow is neg and earnings not until early August. I have set alerts for a break out. There's no reason to enter here as today's candle is a shooting star at the top BB. The foxhole is just too cozy to jump out of yet.
  • Onthemark: @geotheo $SPRY I have a large position built up since last year, and just waiting for the FDA approval which may not occur until the Fall, but in the meantime none of the institutions are selling, just waiting for the big pop when the news happens.
  • geotheo: @Onthemark $SPRY Kind of a high squeeze but I took a 1000 when it pulled back with a stop below today's low. Maybe something will be leaked early. I like it when they go up fast. More fun than kicking mules.
  • Onthemark: $SPRY at $9.38 looks to be heading to $10. Submits Response for Marketing Authorization Application to Europe and Enters License Agreement for commercialization in Australia and New Zealand.
  • Onthemark: Those I own holding up well besides $GCT are $SCHW, $SPRY and $DKNG
  • Onthemark: $SPRY on sale for no apparent reason. FDA approval is pending in the next few months.
  • Onthemark: Long on a few bio-techs from below: $SPRY, $CADL and $MNMD.
  • Onthemark: $SPRY hope some of you joined me on this biotech, took a little of the table at $11. Up 12 percent, Long as more to come.
  • camaro69: @Onthemark $SPRY It's been nice. Thanks
  • Onthemark: $SPRY breaking out. Long from way below and adding on dips.
  • Onthemark: $SPRY, $VKTX and $HIMS doing well today. Long all.
  • Onthemark: $SPRY has now cleared the $9 resistance level and ready to march towards $10. Strong chart since November.
  • Onthemark: $SPRY up nicely, and a new PT of $18. Investor Day is this Thursday. FDA resubmission in April. All systems go.
  • Onthemark: @sgiseller $LABU I added as well. Thanks for mentioning $SPRY about a year ago in May. I took a starter back then and really began adding after falling in Sept because of the FDA's request for additional testing results. Riding it from 3 to 9, it's been my biggest winner because of the amount of shares built up. I believe the best is yet to come with the future anticipated FDA approval.
  • Onthemark: $SPRY continues its march upward. My largest position and adding on pullbacks. Expect some volatility with the Investor's Day next Thursday, however the company announced additional uses for the drug for skin disorders. PTs $13 to $19. Thanks to sgiseller for bringing this one up in the forum almost a year ago. Took a starter then been adding beginning with the gap down in Sept. More to come from this one.
  • Onthemark: Sold some $CLSK at 23, still Long. Biggest position is $SPRY, also long $INZY, $EFTR, $EYPT, $LABU, $GTLS, $PANW, $PTLO and $CCL
  • Onthemark: $SPRY sold a small piece today with the big move, holding an investment portion. Holding an Investor's Day on 3/7 to spread the great results news.
  • Setshot: @Onthemark $SPRY - I bought some of this a week or two ago and am very happy. Did I get the idea from you? If so,thanks.
  • Onthemark: Keep an eye out on $SPRY, reported positive topline results.
  • Onthemark: @Onthemark $SPRY Got some at 6.935 with the initial gap down and the stock has now bounced off the 21 day and moving higher along and above the 8 day. Chart pattern looking good.
  • Onthemark: $SPRY is off to the races
  • Onthemark: @Lou $ARDX Yes, thanks woodman. Doing very well with $SPRY that I mentioned way back. Just waiting for the FDA approval which is forthcoming. Wedbush raised to $19. This will replace the epipens with a nasal spray.
  • Lou: Thanks to @woodman and others, I've built a biotech portfolio that consists of too many stocks, but some are way over full positions and some are just scout positions to watch. My biotechs are: $ARDX – now very large $CLRB – midling $DAWN – moderate $EFTR – small $HIMS – new small $HUMA – brand new, small $INZY – Full $LFMD – small $MREO – moderate $PDSB – Moderate $SPRY – small $VKNG - large
  • Lou: @Lou $ARDX $CLRB $DAWN $EFTR $HIMS $HUMA $INZY $LFMD $MREO $PDSB $SPRY $VKTX Typo - that was $VKTX not VKNG
  • woodman: @Lou $ARDX $CLRB $DAWN $EFTR $HIMS $HUMA $INZY $LFMD $MREO $PDSB $SPRY $VKNG $VKTX - The biotechs are addictive, especially when they are kicking a$$ as the ones we're in are doing. (Though, you never know when a rug-pull is coming, but let's not discuss that on a Friday.)
  • Onthemark: Great day for bio-techs and the etf, $SPRY, $INZY, $ARDX and $LABU. Have a great weekend all!
  • Onthemark: $SPRY up 2.3 percent premarket
  • Onthemark: $SPRY support at the 8d on the minor pullback, looking to bounce again
  • Onthemark: $MREO, $ARDX and $SPRY moving nicely today.
  • Onthemark: Took some partial profits on $SPRY, which is headed higher as it trends up the 8d, Like $MREO at $3 and holding some $HRTX.
  • Onthemark: Up over 100 percent since Nov on $SPRY, and the best is yet to come on this one. Long.
  • Onthemark: Also holding $ARDX and $SPRY, which are taking a little break today.
  • Onthemark: @woodman $MDXH I did get some more $SPRY at 5.72 today. Resistance is at 6 at the 200d, but it keeps chugging along to fill the gap up to 7. Started buying back in Sept at 3. Wedbush gives it an Outperform and a PT of 13.
  • Onthemark: Riding $SPRY as it fills the gap, now over the 200d. Mentioned this last month when it was around $5.20 now over $6. FDA approval expected later this year, which could push this for a double.
  • Onthemark: @champ $GTLS $JPM #News-flow #might Been long $GTLS, also liking other longs $SPRY, $TLRY, $HTZ, and $OLLI
  • champ: @Onthemark $GTLS $JPM $SPRY $TLRY $HTZ $OLLI #News-flow #might....Real nice and I'm also holding $OLLI and it is my #largest-position.....and I will check out those other 3....Good Luck!
  • Onthemark: @woodman $ARDX Yes, thank you for letting all of us know about this company when it was so much lower. Those that got involved should have done quite well so far, and look forward to higher prices. If I can return the favor, I would point out $SPRY as a good 2024 story, since it did receive FDA committee approval for its nasal spray in 2023 only to be asked for addition results which will be provided in the first half of 2024. The stock did drop on the disappointment, but has been in a basing pattern, with a slight upward bias.
  • Onthemark: $SPRY Filling up the gap as it rides up the 8dma. Approval of the nasal spray expected next year.
  • oldmaratom: $SPRY#Wedbush analyst Andreas Arygrides maintains outperform with $13 pt.
  • Onthemark: $SPRY, $LABU, $ETHE, $COIN and $GBTC Long and added to each
  • Onthemark: @champ #TGIFriday #Great-Weekend Have a great weekend too. As a spec take a look at $SPRY. It's filling the gap now.
  • Zimzala: $SPRY On the move. Only have a tracking position.
Visit the Trading Forum to join in the discussion.
Stock Price $13.50
Change -9.21%
Volume 3,133,140

ARS Pharmaceuticals Inc is a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis. The company is developing neffy, an intranasal epinephrine product in clinical development for patients and their caregivers with Type I allergic reactions including food, medications, and insect bites that could lead to life-threatening anaphylaxis.

Request Video of SPRY
Already a member? Sign in here.
Past Month

Leading Peers

Past Month

Lagging Peers

Dan Fitzpatrick

Stock Market Mentor gives you EVERYTHING you need to succeed in the market; all in one place. How easy is that? Dan Fitzpatrick and his elite community of traders share trading ideas, strategies and much more. Dan Fitzpatrick--a world class Technical Analyst, trading coach and regular CNBC contributor--gives you access to all of this with a 30 day trial membership for just $7.77. Get started TODAY and start trading better TOMORROW with the following premium content:

  • Nightly video Strategy Sessions with a game plan for tomorrow
  • Got a stock you want Dan to look at? Just ask.
  • Patent pending video alerts instantly delivered to you when one of Dan’s trading signals is triggered. This is not your typical price alert. This is a short video explaining the action you need to take to make money. No more “Woulda, coulda, shoulda”
  • Access to over 90,400 stock analysis videos
  • Access an ever expanding library (90,400) of educational videos that will save you time and make you money

Join a team of friends and traders that have one thing in common; a burning desire to succeed.

Become a Member Today!

Gain immediate access to all our exclusive articles, features, how-to's, discussion group and much more...

Satisfaction Guaranteed!

Your Stock Market Mentor membership comes with a 30 day, no questions asked, 100% money back guarantee!